Texas Back Institute is a world leader in advancing spine technology, science, and education, as well as patient careCLARITY is a randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., May 12, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ...

BELO HORIZONTE, Brazil, May 12, 2025 (GLOBE NEWSWIRE) -- Inter&Co Inc. (NASDAQ: INTR | B3: INBR32), the leading financial super app providing financial and digital commerce services to 37.7 million customers, today reported financial results for the first quarter of 2025. 1Q25 Highlights: Total clients grew to 37.7 million, with 21.6 million active clients and an activation rate of 57.2%.Net Income of R$287 million, excluding minority interests, up 57% YoY.Return on Equity of 12.9%, up from 9.2% in 1Q24.Eff ...

文章核心观点 挪威最大在线药房Farmasiet为挖掘业务潜力与Agillic签约，采用其平台推出定制解决方案 [1][2][3] 合作双方情况 - Farmasiet是挪威最大在线药房，可配送处方药、非处方药和日用品，有在线药剂师提供建议 [1] - Agillic是丹麦软件公司，提供数据驱动平台，可实现个性化沟通，总部位于哥本哈根 [5] 合作原因 - Farmasiet认为先进客户参与有业务价值和潜力，需新平台实现目标，选择标准为技术能支持想法且符合欧洲数据隐私安全法规 [2] - Farmasiet认为Agillic平台能执行其想法并挖掘潜力，且不影响上市时间；Agillic平台符合合规要求且可扩展客户旅程 [4] 合作成果 - Farmasiet在六周内推出含电商集成、高级客户旅程等的定制解决方案 [3]

文章核心观点 公司公布2024年12月31日年度报告已发布或提供给股东，报告含2025年6月19日年度股东大会通知，还提交至金融行为监管局电子提交系统 [1][2] 分组1 - 年度报告情况 - 公司2024年12月31日年度报告已发布或提供给股东，可在公司网站查看 [1] - 年度报告含2025年6月19日年度股东大会通知 [1] 分组2 - 报告提交与查询 - 年度报告和代理表格已提交至金融行为监管局电子提交系统，可在指定网址查看 [2] 分组3 - 联系方式 - 如需进一步信息可联系Rachel Peat，电话+44 (0)80 0316 2067 [2]

文章核心观点 - Longeveron公司入选XPRIZE Healthspan竞赛半决赛队伍并获25万美元里程碑1奖项，其干细胞疗法laromestorcel有潜力治疗多种疾病且已获多项FDA指定 [1][2] 关于XPRIZE Healthspan竞赛 - 这是一项为期7年、奖金1.01亿美元的全球竞赛，旨在革新人类衰老应对方式 [2][4] - 参赛团队需开发测试能恢复肌肉、认知和免疫功能至少10年（目标20年）的疗法 [4] - 超600个来自58个国家的申请团队中，前100名成为半决赛队伍，前40名获25万美元奖金，半决赛队伍有资格竞争100万美元里程碑奖，大奖奖金6100万 - 8100万美元 [2] 关于Longeveron公司 - 是临床阶段再生医学生物技术公司，开发细胞疗法治疗危及生命和慢性衰老相关疾病 [1] - 主要研究产品laromestrocel是同种异体间充质干细胞疗法，有多种潜在作用机制，可用于多种疾病领域 [6] - 目前正在推进HLHS、阿尔茨海默病和衰老相关虚弱三个管线适应症的研究 [6] - laromestrocel开发项目获五项FDA指定，HLHS项目获孤儿药指定、快速通道指定和罕见儿科疾病指定，阿尔茨海默病项目获再生医学先进疗法指定和快速通道指定 [2][6]

Press Release Eviden Awarded Contract for “Kaufhaus des Bundes - Next Generation” Project by the Procurement Office of the Federal Ministry of the Interior (BeschA) Together with veenion, Eviden is redesigning the 'KdB NG' procurement platform for more than 480 federal authorities and federal-related institutions Berlin, Deutschland, and Paris, France – May 12, 2025 – Eviden, the Atos Group business leading in digital, cloud, big data and security and IT partner veenion GmbH announce the successful signing ...

Underreported D.E.A. Letter and Policy Position Could be a Game Changer for Mushroom Enthusiasts An Emerging Markets Sponsored Commentary ORLANDO, Fla., May 12, 2025 (GLOBE NEWSWIRE) -- At the Emerging Market Report we are comprised of a team of veteran journalists, authors, former stock brokers, financial professionals, and unabashed opportunists who all come together to publish these tidy missives on our client profiles. We are constantly searching for impactful news that could be gamechangers for the Com ...

This New ESA terminal complements Stellar Blu Sidewinder solutions, positioning Gilat to serve both business and defense aviation markets with a comprehensive multi-orbit offeringPETAH TIKVA, Israel, May 12, 2025 (GLOBE NEWSWIRE) -- Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions and services, announced today the successful completion of a series of test flights featuring its ESR-2030Ku electronically steered antenna (ESA). Conducted ...

Multiple HCPs have requested from Invivyd a monoclonal antibody (mAb) for treatment of active measles infection and post-exposure prophylaxis to reduce the consequence of outbreaks. Such a medicine could accelerate the pathway to functional eradication of measlesMeasles (rubeola) virus appears to offer an attractive target for best-in-class monoclonal antibody discovery and development utilizing Invivyd technologyMore than 20 million Americans are unvaccinated against measles; U.S. is at risk for losing fun ...

Dorel Juvenile reports strong performanceDorel Home taking further steps to return to profitability MONTRÉAL, May 12, 2025 (GLOBE NEWSWIRE) -- Dorel Industries Inc. (TSX: DII.B, DII.A) today announced its financial results for the first quarter ended March 31, 2025.First quarter revenue was US$320.5 million, down 8.7%, from US$351.1 million a year ago. Reported net loss for the quarter was US$25.3 million or US$0.77 per diluted share compared to US$17.6 million or US$0.54 per diluted share a year ago. The r ...